Shares of Vascular Biogenics Ltd. (NASDAQ:VBLT) have earned an average recommendation of “Buy” from the six brokerages that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $16.00.
Several research analysts have commented on the company. ValuEngine raised Vascular Biogenics from a “sell” rating to a “hold” rating in a research report on Wednesday, September 20th. HC Wainwright reissued a “buy” rating and issued a $11.00 price objective on shares of Vascular Biogenics in a research report on Tuesday. Chardan Capital raised their price objective on Vascular Biogenics from $20.00 to $25.00 and gave the company a “buy” rating in a research report on Monday. Finally, Zacks Investment Research raised Vascular Biogenics from a “sell” rating to a “hold” rating in a research report on Wednesday, October 18th.
Vascular Biogenics (NASDAQ VBLT) traded up $0.55 during trading hours on Friday, reaching $7.35. The company’s stock had a trading volume of 456,340 shares, compared to its average volume of 265,423. Vascular Biogenics has a one year low of $3.90 and a one year high of $7.35.
Vascular Biogenics (NASDAQ:VBLT) last released its quarterly earnings data on Monday, August 14th. The biopharmaceutical company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.01. equities research analysts anticipate that Vascular Biogenics will post -0.81 EPS for the current fiscal year.
An institutional investor recently bought a new position in Vascular Biogenics stock. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Vascular Biogenics Ltd. (NASDAQ:VBLT) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 22,100 shares of the biopharmaceutical company’s stock, valued at approximately $135,000. Zurcher Kantonalbank Zurich Cantonalbank owned about 0.08% of Vascular Biogenics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 11.17% of the company’s stock.
Vascular Biogenics Company Profile
Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.
Receive News & Ratings for Vascular Biogenics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.